Eli Lilly oral weight-loss drug shows superior efficacy vs Novo's Wegovy in indirect comparison

Eli Lilly presented data at EASD from an indirect comparison showing its oral weight-loss drug Fundayo (orforglipron) achieved significantly greater weight loss and better blood sugar control than Novo Nordisk's oral semaglutide (Wegovy). The comparison is indirect, not head-to-head, so results should be interpreted cautiously. This intensifies competitive pressure in the GLP-1 market, potentially impacting Novo's market share and pricing dynamics.